Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone Methyl in CKD at Risk of Rapid Progression
NCT04702997Phase 2Completed
- Sponsor
- Biogen
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bardoxolone methyl in chronic kidney disease (CKD), sponsored by Biogen. Started Feb 2021; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04702997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702997.